Literature DB >> 2384581

Determination of the active metabolite of molsidomine in human plasma by reversed-phase high-performance liquid chromatography.

C Dutot1, J Moreau, P Cordonnier, O Spreux-Varoquaux, C Klein, J Ostrowski, C Advenier, W Gärtner, M Pays.   

Abstract

A reversed-phase high-performance liquid chromatographic method, with ultraviolet detection, is proposed for the plasma determination of SIN-1, the active metabolite of molsidomine, which involves propoxycarbonyl derivatization. The internal standard is the ethoxycarbonyl derivative of SIN-1 (i.e. molsidomine). Derivatization and extraction are each performed in one step (2 min) with 70% yield. The nature of a by-product is discussed. The method provides rapid elution (less than 15 min), linearity over the range 0.4-200 ng/ml, day-to-day precision between 2.5 and 11.3% and a limit of determination of 0.5 ng/ml. This method is also suitable for the simultaneous determination of molsidomine and SIN-1. In this case the internal standard is an ethoxycarbonyl derivative of a piperazino-3-sydnonimine, a SIN-1 analogue.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2384581     DOI: 10.1016/s0378-4347(00)82401-9

Source DB:  PubMed          Journal:  J Chromatogr


  2 in total

1.  Pharmacokinetic profile of a novel slow release preparation of molsidomine.

Authors:  S Rietbrock; B Keller-Stanislawski; P Thürmann; D Brockmeier
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Pharmacokinetics of molsidomine and its active metabolite, linsidomine, in patients with liver cirrhosis.

Authors:  O Spreux-Varoquaux; J Doll; C Dutot; N Grandjean; P Cordonnier; M Pays; J Andrieu; C Advenier
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.